Dipna Pharmachem (BOM:543594) Beneish M-Score: 4593.97 (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543594 Dipna Pharmachem Ltd BOM:543594
62 GF Score
Price ₹4.89
GF Value ₹9.16
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Dipna Pharmachem Beneish M-Score?

Dipna Pharmachem BOM:543594 +9.64% 62 Beneish M-Score is 4593.97 as of Aug. 08, 2026. GuruFocus rates BOM:543594 with a GF Score™ of 62/100 and a GF Value™ of ₹9.16 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 625 Healthcare Providers & Services companies, Dipna Pharmachem ranks worse than 100% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 4593.97 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Dipna Pharmachem's Beneish M-Score or its related term are showing as below:

BOM:543594' s Beneish M-Score Range Over the Past 10 Years
Min: -1.84   Med: -0.23   Max: 4593.97
Current: 4593.97

During the past 7 years, the highest Beneish M-Score of Dipna Pharmachem was 4593.97. The lowest was -1.84. And the median was -0.23.


Dipna Pharmachem Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Dipna Pharmachem's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dipna Pharmachem Beneish M-Score Chart

Dipna Pharmachem Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 -0.23 -1.84 4,593.97

Dipna Pharmachem Semi-Annual Data
Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 0.00 -1.84 0.00 4,593.97

Dipna Pharmachem Beneish M-Score Competitor Comparison

For the Pharmaceutical Retailers subindustry, Dipna Pharmachem's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dipna Pharmachem Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Dipna Pharmachem's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Dipna Pharmachem's Beneish M-Score falls into.


BOM:543594
62GF Score
Dipna Pharmachem Ltd BOM:543594
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dipna Pharmachem Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Dipna Pharmachem for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.4877+0.528 * 1.8682+0.404 * 11376.8636+0.892 * 0.9677+0.115 * 1.2048
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * 0.09384-0.327 * 0.9828
=4,593.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹480 Mil.
Revenue was ₹1,249 Mil.
Gross Profit was ₹112 Mil.
Total Current Assets was ₹1,541 Mil.
Total Assets was ₹2,056 Mil.
Property, Plant and Equipment(Net PPE) was ₹1 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹0 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹1,332 Mil.
Long-Term Debt & Capital Lease Obligation was ₹101 Mil.
Net Income was ₹10 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹-183 Mil.
Total Receivables was ₹1,017 Mil.
Revenue was ₹1,291 Mil.
Gross Profit was ₹216 Mil.
Total Current Assets was ₹1,323 Mil.
Total Assets was ₹1,324 Mil.
Property, Plant and Equipment(Net PPE) was ₹0 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹0 Mil.
Selling, General, & Admin. Expense(SGA) was ₹11 Mil.
Total Current Liabilities was ₹850 Mil.
Long-Term Debt & Capital Lease Obligation was ₹89 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(480.045 / 1249.171) / (1017.127 / 1290.833)
=0.384291 / 0.787962
=0.4877

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(216.018 / 1290.833) / (111.899 / 1249.171)
=0.167348 / 0.089579
=1.8682

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1540.899 + 0.723) / 2056.294) / (1 - (1323.303 + 0.459) / 1323.791)
=0.250291 / 2.2E-5
=11376.8636

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1249.171 / 1290.833
=0.9677

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.114 / (0.114 + 0.459)) / (0.143 / (0.143 + 0.723))
=0.198953 / 0.165127
=1.2048

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 1249.171) / (11.13 / 1290.833)
=0 / 0.008622
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((101.001 + 1332.26) / 2056.294) / ((88.903 + 849.96) / 1323.791)
=0.697012 / 0.709223
=0.9828

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(9.74 - 0 - -183.223) / 2056.294
=0.09384

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Dipna Pharmachem has a M-score of 4,593.97 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 4593.97 mean?
Dipna Pharmachem (BOM:543594) has a Beneish M-Score of 4593.97 as of Aug. 08, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Dipna Pharmachem and its competitors. According to the industry distribution chart, Dipna Pharmachem ranks #625 out of 625 companies in the Healthcare Providers & Services industry.
Is Dipna Pharmachem's Beneish M-Score too high?
Dipna Pharmachem's current Beneish M-Score is 4593.97. Based on the distribution chart, Dipna Pharmachem ranks #625 out of 625 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Dipna Pharmachem has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dipna Pharmachem's Beneish M-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Dipna Pharmachem ranks #625 out of 625 companies for Beneish M-Score. This places Dipna Pharmachem in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Dipna Pharmachem and its competitors. Dipna Pharmachem's current Beneish M-Score is 4593.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dipna Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Dipna Pharmachem (BOM:543594) is currently considered Possible Value Trap. The stock's GF Value™ is ₹9.16, compared to a current price of ₹4.89 — trading 46.6% below its estimated fair value. The current Beneish M-Score is 4593.97. Dipna Pharmachem's overall GF Score™ is 62/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Dipna Pharmachem (BOM:543594), the current Beneish M-Score is 4593.97 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dipna Pharmachem (BOM:543594) Overvalued in 2026?

Based on GuruFocus' analysis, Dipna Pharmachem stock appears to be undervalued. The current stock price of ₹4.89 is trading 46.6% below its estimated GF Value™ of ₹9.16. GuruFocus considers Dipna Pharmachem to be Possible Value Trap.

Key valuation signals for BOM:543594:

  • Beneish M-Score: 4593.97
  • GF Value™: ₹9.16 vs. price of ₹4.89 (46.6% below fair value)
  • GF Score™: 62/100 with 9 warning signs

No single metric tells the full story. See the BOM:543594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dipna Pharmachem Business Description

Address A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad, GJ, IND, 380055
Dipna Pharmachem Ltd is engaged in the trading and distribution of a wide range of pharmaceutical raw materials which is also known as APIs (Active Pharmaceutical Ingredients), Excipient and chemical formulation products. The company's product portfolio comprises of Hydrocortisone Acetate, Aceclofenac, Asprin, Levofloxacin, and others.
62GF Score

Get the complete analysis for BOM:543594

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹4.89
Price
₹9.16
GF Value